Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Sep 25, 2019

Provention Bio to Present at the 2019 Cantor Global Healthcare Conference
Sep 24, 2019

Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing

- FDA Meeting Expected in Q4 2019 and BLA Submission for PRV-031 (teplizumab) Targeted for Q4 2020 -
Sep 20, 2019

The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Sep 18, 2019

Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock
Sep 18, 2019

Provention Bio Announces Proposed Public Offering of Common Stock

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.